Low-dose aspirin in the primary prevention of cardiovascular diseases: A retrospective, propensity score matched study.

[1]  C. Mangione,et al.  US Preventive Services Task Force Recommendation Statement on Screening for Atrial Fibrillation-Reply. , 2022, JAMA.

[2]  L. Perdue,et al.  Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. , 2022, JAMA.

[3]  J. Staessen,et al.  Aspirin use is associated with increased risk for incident heart failure: a patient‐level pooled analysis , 2021, ESC heart failure.

[4]  Yiping Wei,et al.  Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis , 2020, Frontiers in Pharmacology.

[5]  Haojun Song,et al.  Effects of aspirin on the gastrointestinal tract: Pros vs. cons , 2020, Oncology letters.

[6]  Deepak L. Bhatt,et al.  Aspirin for Primary Prevention of Cardiovascular Events. , 2019, Journal of the American College of Cardiology.

[7]  G. Parati,et al.  ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison. , 2019, Journal of the American College of Cardiology.

[8]  Deepak L. Bhatt,et al.  The rise and fall of aspirin in the primary prevention of cardiovascular disease , 2019, The Lancet.

[9]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[10]  J. Gagne,et al.  Using Real‐World Data to Extrapolate Evidence From Randomized Controlled Trials , 2018, Clinical pharmacology and therapeutics.

[11]  R. Collins,et al.  Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.

[12]  R. Caporali,et al.  Randomized controlled trials and real-world data: differences and similarities to untangle literature data. , 2018, Rheumatology.

[13]  Suzanne G. Orchard,et al.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly , 2018, The New England journal of medicine.

[14]  P. Rothwell,et al.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial , 2018, The Lancet.

[15]  J. Douketis,et al.  2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. , 2017, The Canadian journal of cardiology.

[16]  E. Whitlock,et al.  Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[17]  Kirsten Bibbins-Domingo,et al.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.

[18]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[19]  Shunichi Homma,et al.  Warfarin and aspirin in patients with heart failure and sinus rhythm. , 2012, The New England journal of medicine.

[20]  M. O’Donnell,et al.  Effect of aspirin on mortality in the primary prevention of cardiovascular disease. , 2011, The American journal of medicine.

[21]  G. Howard,et al.  Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. , 2011, The American journal of cardiology.

[22]  Xiaoying Li,et al.  Risk assessment and aspirin use in Asian and Western populations , 2010, Vascular health and risk management.

[23]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[24]  Adam J. Hoffhines,et al.  The discovery of aspirin's antithrombotic effects. , 2007, Texas Heart Institute journal.

[25]  J. Segal,et al.  Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men , 2006, Journal of the American Medical Association (JAMA).

[26]  Gianni Tognoni,et al.  Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.

[27]  J. Manson,et al.  A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2005, The New England journal of medicine.

[28]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[29]  S. Straus,et al.  New evidence for stroke prevention: scientific review. , 2002, JAMA.

[30]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[31]  E. Topol,et al.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease. , 2001, The American journal of cardiology.

[32]  M. Roncaglioni.  Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.

[33]  R. Kronmal,et al.  Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. , 2000, Archives of neurology.

[34]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[35]  G. Escolar,et al.  Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium. , 1986, Thrombosis Research.